Synergistic Role between p53 and JWA: Prognostic and Predictive Biomarkers in Gastric Cancer

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Liu, Xin ^a   Wang, Shouyu ^a   Xia, Xiaowei ^a   Chen, Yansu ^a   Zhou, Yan ^b   Wu, Xuming ^a,c   Zhang, Jianbing ^a,c   He, Song ^c   Tan, Yongfei ^b   Qiang, Fulin ^c   Røe, Oluf Dimitri ^d   Li, Gang ^e   Zhou, Jianwei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Yixing Hospital   (China)

^c Nantong Cancer Hospital   (China)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLATINUM COMPLEX; PROTEIN JWA; PROTEIN P53; TUMOR MARKER; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GASTRECTOMY; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR INTERACTION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RETROSPECTIVE STUDY; STOMACH CANCER;

FEMALE; HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84871352311     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052348     Document Type: Article

References (48)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Cunningham D, Chua YJ, (2007) East meets west in the treatment of gastric cancer. N Engl J Med 357: 1863-1865.
3. Wagner AD, Moehler M, (2009) Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Curr Opin Oncol 21: 381-385.
4. Wu A, Ji J, (2008) Adjuvant chemotherapy for gastric cancer or not: a dilemma? J Natl Cancer Inst 100: 376-377.
5. Vousden KH, Lane DP, (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8: 275-283.
6. Muller PA, Vousden KH, Norman JC, (2011) p53 and its mutants in tumor cell migration and invasion. J Cell Biol 192: 209-218.
7. Melino G, (2011) p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ 18: 1487-1499.
8. Hanel W, Moll UM, (2012) Links between mutant p53 and genomic instability. J Cell Biochem 113: 433-439.
9. Goh AM, Coffill CR, Lane DP, (2011) The role of mutant p53 in human cancer. J Pathol 223: 116-126.
10. Alsner J, Jensen V, Kyndi M, Offersen BV, Vu P, et al. (2008) A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol 47: 600-607.
11. Maslon MM, Hupp TR, (2010) Drug discovery and mutant p53. Trends Cell Biol 20: 542-555.
12. Goldstein I, Marcel V, Olivier M, Oren M, Rotter V, et al. (2011) Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther 18: 2-11.
13. Machado-Silva A, Perrier S, Bourdon JC, (2010) p53 family members in cancer diagnosis and treatment. Semin Cancer Biol 20: 57-62.
14. Liu X, Cai H, Huang H, Long Z, Shi Y, et al. (2011) The prognostic significance of apoptosis-related biological markers in Chinese gastric cancer patients. PLoS One 6: e29670.
15. Coutant C, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, et al. (2011) Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers. Clin Cancer Res 17: 2591-2601.
16. Bourdon JC, Khoury MP, Diot A, Baker L, Fernandes K, et al. (2011) p53 mutant breast cancer patients expressing p53gamma have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res 13: R7.
17. Chen R, Qiu W, Liu Z, Cao X, Zhu T, et al. (2007) Identification of JWA as a novel functional gene responsive to environmental oxidative stress induced by benzo[a]pyrene and hydrogen peroxide. Free Radic Biol Med 42: 1704-1714.
18. Wang S, Gong Z, Chen R, Liu Y, Li A, et al. (2009) JWA regulates XRCC1 and functions as a novel base excision repair protein in oxidative-stress-induced DNA single-strand breaks. Nucleic Acids Res 37: 1936-1950.
19. Wang S, Wu X, Chen Y, Zhang J, Ding J, et al. (2012) Prognostic and Predictive Role of JWA and XRCC1 Expressions in Gastric Cancer. Clin Cancer Res 18: 2987-2996.
20. Tang WY, Wang L, Li C, Hu ZB, Chen R, et al. (2007) Identification and functional characterization of JWA polymorphisms and their association with risk of gastric cancer and esophageal squamous cell carcinoma in a Chinese population. J Toxicol Environ Health A 70: 885-894.
21. Sakamoto H, Yoshimura K, Saeki N, Katai H, Shimoda T, et al. (2008) Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet 40: 730-740.
22. Aiko T, Sasako M, (1998) The new Japanese Classification of Gastric Carcinoma: Points to be revised. Gastric Cancer 1: 25-30.
23. Weichert W, Roske A, Gekeler V, Beckers T, Ebert MP, et al. (2008) Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 9: 139-148.
24. Allum WH, Blazeby JM, Griffin SM, Cunningham D, Jankowski JA, et al. (2011) Guidelines for the management of oesophageal and gastric cancer. Gut 60: 1449-1472.
25. Brosh R, Rotter V, (2009) When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9: 701-713.
26. Maehara Y, Tomoda M, Hasuda S, Kabashima A, Tokunaga E, et al. (1999) Prognostic value of p53 protein expression for patients with gastric cancer-a multivariate analysis. Br J Cancer 79: 1255-1261.
27. Li X, Cheung KF, Ma X, Tian L, Zhao J, et al. (2011) Epigenetic inactivation of paired box gene 5, a novel tumor suppressor gene, through direct upregulation of p53 is associated with prognosis in gastric cancer patients. Oncogene.
28. Gamboa-Dominguez A, Seidl S, Reyes-Gutierrez E, Hermannstadter C, Quintanilla-Martinez L, et al. (2007) Prognostic significance of p21WAF1/CIP1, p27Kip1, p53 and E-cadherin expression in gastric cancer. J Clin Pathol 60: 756-761.
29. Yokobori T, Mimori K, Iwatsuki M, Ishii H, Onoyama I, et al. (2009) p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res 69: 3788-3794.
30. Sumiyoshi Y, Kakeji Y, Egashira A, Mizokami K, Orita H, et al. (2006) Overexpression of hypoxia-inducible factor 1alpha and p53 is a marker for an unfavorable prognosis in gastric cancer. Clin Cancer Res 12: 5112-5117.
31. Wu CW, Lin YY, Chen GD, Chi CW, Carbone DP, et al. (1999) Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade. Br J Cancer 80: 483-488.
32. Zhang J, He XH, Xie XY, Hu X, He C, (2010) The potential for serum p53 to predict the response to chemotherapy of patients with gastric cancer. J Int Med Res 38: 423-431.
33. Cheok CF, Verma CS, Baselga J, Lane DP, (2011) Translating p53 into the clinic. Nat Rev Clin Oncol 8: 25-37.
34. Wang Y, Suh YA, Fuller MY, Jackson JG, Xiong S, et al. (2011) Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest 121: 893-904.
35. Issaeva N, Friedler A, Bozko P, Wiman KG, Fersht AR, et al. (2003) Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc Natl Acad Sci U S A 100: 13303-13307.
36. Jackson JG, Pant V, Li Q, Chang LL, Quintas-Cardama A, et al. (2012) p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast Cancer. Cancer Cell 21: 793-806.
37. Huang Y, Jeong JS, Okamura J, Sook-Kim M, Zhu H, et al. (2012) Global tumor protein p53/p63 interactome: Making a case for cisplatin chemoresistance. Cell Cycle 11: 2367-2379.
38. Ferreira CG, Tolis C, Giaccone G, (1999) p53 and chemosensitivity. Ann Oncol 10: 1011-1021.
39. Yang H, He L, Kruk P, Nicosia SV, Cheng JQ, (2006) Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer 119: 2304-2312.
40. Ueno Y, Enomoto T, Otsuki Y, Sugita N, Nakashima R, et al. (2006) Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin. Cancer Lett 241: 289-300.
41. Chang FL, Ling YF, Lai MD, (2000) Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells. Anticancer Res 20: 329-336.
42. Bai J, Zhang J, Wu J, Shen L, Zeng J, et al. (2010) JWA regulates melanoma metastasis by integrin alphaVbeta3 signaling. Oncogene 29: 1227-1237.
43. Huang S, Shen Q, Mao WG, Li AP, Ye J, et al. (2006) JWA, a novel signaling molecule, involved in the induction of differentiation of human myeloid leukemia cells. Biochem Biophys Res Commun 341: 440-450.
44. Chen H, Bai J, Ye J, Liu Z, Chen R, et al. (2007) JWA as a functional molecule to regulate cancer cells migration via MAPK cascades and F-actin cytoskeleton. Cell Signal 19: 1315-1327.
45. Zurer I, Hofseth LJ, Cohen Y, Xu-Welliver M, Hussain SP, et al. (2004) The role of p53 in base excision repair following genotoxic stress. Carcinogenesis 25: 11-19.
46. Avkin S, Sevilya Z, Toube L, Geacintov N, Chaney SG, et al. (2006) p53 and p21 regulate error-prone DNA repair to yield a lower mutation load. Mol Cell 22: 407-413.
47. Bartek J, Lukas J, Bartkova J, (2007) DNA damage response as an anti-cancer barrier: damage threshold and the concept of 'conditional haploinsufficiency'. Cell Cycle 6: 2344-2347.
48. Mallette FA, Ferbeyre G, (2007) The DNA damage signaling pathway connects oncogenic stress to cellular senescence. Cell Cycle 6: 1831-1836.